Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Proton Pump Inhibitors, or Metoclopramide: A Population-Based Nested Case-Control Study

Abstract

IntroductionEpidemiological studies have linked domperidone use with serious cardiac arrhythmias, including sudden cardiac death, but data on age, dose, and duration of use are limited.ObjectivesThe aim of this study was to assess the risk of out-of-hospital sudden cardiac death associated with domperidone use versus proton pump inhibitors (PPIs), metoclopramide, or non-use of all three medications, and to evaluate the risk of sudden cardiac death in relation to age and domperidone dose.MethodsThis was a population-based case-control study nested in a cohort of subjects aged ≥2 years in the Clinical Practice Research Datalink with one or more prescriptions for domperidone, any PPI, or metoclopramide from 2005 to 2011. Out-of-hospital sudden cardiac death was assessed by linkage with Hospital Episode Statistics and death certificates. Controls were matched on age, sex, and medical practice. The risk of sudden cardiac death in domperidone users versus risk in users of PPIs or metoclopramide was evaluated with multivariable conditional logistic regression; case-crossover analysis addressed possible residual confounding.ResultsFrom the study cohort (n = 681,104), 3239 sudden cardiac death cases were matched to 12,572 controls. The adjusted odds ratio (95 % confidence interval) for sudden cardiac death with current use of domperidone alone was 1.71 (0.92–3.18) versus non-use of study medications, 1.26 (0.68–2.34) versus current PPI use, and 0.40 (0.17–0.94) current metoclopramide use. The adjusted odds ratio (95 % confidence interval) relative to exposure to no study drug for domperidone >30 mg/day (eight cases, five controls) was 3.20 (0.59–17.3) and 1.65 (0.89–3.07) for age ≥61 years (27 cases, 49 controls). The odds ratio (95 % confidence interval) was 3.17 (1.72–5.83) for within-person periods of domperidone use versus non-use in the case-crossover analysis.ConclusionsCompared with non-use of any study drug, current domperidone use was associated with sudden cardiac death in nested case-control and case-crossover analyses, with a suggestion of higher risk in older persons and users of higher daily doses.Electronic supplementary materialThe online version of this article (doi:10.1007/s40264-015-0338-0) contains supplementary material, which is available to authorized users.

Increased risk of all‐cause mortality associated with domperidone use in Parkinson's patients: a population‐based cohort study in the UK

“…Previous literature on domperidone that evaluated the association with sudden cardiac death (SCD) in the general population suggested that domperidone was associated with an increased risk of cardiac adverse events, including mortality . Interestingly, in a study by Arana and colleagues, it was identified that the risk for sudden cardiac death was concentrated within 15 days from first domperidone exposure . This finding supports our results showing an elevated risk for all‐cause mortality within the first month of use.…”

A comparative pharmacokinetic study of three flavonoids and three anthraquinones in normal and gastrointestinal motility disorders rat plasma after the oral administration of Wei‐Chang‐Shu tablet using high‐performance liquid chromatography–tandem mass spectrometry

“…At present, the most commonly used drugs for the treatment of GMD are cisapride and domperidone. Although both drugs have been used in the treatment of GMD with relatively good therapeutic effects (Chen et al, ; Veysey et al, ), they are associated with adverse cardiovascular events (Arana et al, ; Tréluyer, Rey, Sonnier, Pons, & Cresteil, ). Cisapride was withdrawn from the global market in 2000 (Department of Health, ).…”

In Silico Study of Metoclopramide as A Small Molecule of Dopamine D2 Receptor: a Quantum-Mechanical (QM) Based Molecular Docking Treatment

“…In recent years, antagonist drugs have shown better properties than agonist compounds for binding with dopamine D2 receptor. The main antagonist drugs are atypical antipsychotics [26], cinnarizine [27], chloroethylnorapomorphine [28], desmethoxyfallypride [29], domperidone [30], metoclopramide [31], eticlopride [32], fallypride [33], hydroxyzine [34] and itopride [35].…”